Costs and Benefits of Branded Drugs: Insights from Cost-Effectiveness Research

نویسندگان

چکیده

Abstract The relationship between costs and health benefits of branded pharmaceuticals remains controversial. This paper examines the incremental incurred for gained from largest available sample cost-effectiveness studies drugs in USA, 1994–2015 Tufts Registry Cost-Effectiveness Analyses. Earlier used small, specialized samples drugs. We use linear regression analysis to estimate association those additional quality-adjusted life years (QALYs) pharmaceutical costs. preferred uses 476 involving with both higher increased effectiveness compared previous standard care. Regressions on QALYs imply that an QALY is associated, average, a $28,561 increase cost (95 % CI, $18,853–$38,270). explains 20 variation In this analytical sample, share is, therefore, not random but rather associated QALYs; prices are some extent “value-based.” Our results robust varying inclusion criteria funding source. subgroup analyses, highest per was $44,367 $35,373–$53,361). Costs data set are, lower than common estimates monetary value American consumers. As other studies, we find sellers patent-protected beneficial new technology appear capture only fraction provided.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Costs, Benefits, and Cost-Effectiveness of Interventions to Reduce Maternal Morbidity and Mortality in Mexico

BACKGROUND In Mexico, the lifetime risk of dying from maternal causes is 1 in 370 compared to 1 in 2,500 in the U.S. Although national efforts have been made to improve maternal services in the last decade, it is unclear if Millennium Development Goal 5--to reduce maternal mortality by three-quarters by 2015--will be met. METHODOLOGY/PRINCIPAL FINDINGS We developed an empirically calibrated m...

متن کامل

Costs and Cost Effectiveness of Additive Manufacturing

............................................................................................................................................... II PREFACE ................................................................................................................................................. IV ACKNOWLEDGEMENTS ...............................................................................

متن کامل

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

BACKGROUND New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown. METHODS We conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified,...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Benefit-cost Analysis

سال: 2022

ISSN: ['2194-5888', '2152-2812']

DOI: https://doi.org/10.1017/bca.2022.12